Author
Centre Hospitalier Universitaire VaudoisORCID 0000-0001-8985-4704Unclaimed ORCID profile · follow to get notified of new preprints
Mutual co-authors in cluster
6 papers
Recent·Most cited
Bovannak Stewen Chap, Tania Santoro, Paris Kosti…·Denarda Dangaj Laniti
The paper uses patient-derived explants to study BiTE-driven T cell responses in tumors, identifying the COX/PGE2 axis as a barrier to immune activation and showing COX inhibition enhances anti-tumor effects.
María Masid, Ioanna A. Rota, David Barras…·Vassily Hatzimanikatis A
This study introduces iMSEA, a computational framework that identifies metabolic state shifts in BRCA1-deficient cancers using omics data and validates findings with experimental assays.
D. Gulhan, David Barras, Marco Mina…·Denarda Dangaj Laniti
This study identifies two immune archetypes in HRD tumors—immune-inflamed and immune-evasive—linked to chromosomal instability and lineage, informing biomarker-driven therapies.
Eleonora Ghisoni, Fabrizio Benedetti, Aspram Minasyan…·Denarda Dangaj Laniti
The paper identifies immune phenotypes and myeloid cell networks in recurrent ovarian cancer that influence prognosis and immune environment reinstatement.
Raquel Buj, Aidan R. Cole, Jeff Danielson…·Katherine M. Aird
This study shows that zinc availability in the tumor microenvironment affects anti-PD1 therapy response in CDKN2A-low tumors through macrophage phagocytosis.
D. Gulhan, Vinay Viswanadham, Francesc Muyas…·Peter J. Park
The paper identifies mutational signatures SBS26 and SBS54 in MMRD tumors that correlate with immune checkpoint blockade response and survival, suggesting their use as prognostic biomarkers.